Reply

We thank Con et  al1 for their comments and their insightful analysis of the results of our study, which explored the relationship between exposure to infliximab and the rate of opportunistic infections in inflammatory bowel disease patients.2 They pointed out the fact that we presented the number of infections ov er a period of time as a linear function of the cumulative exposure to infliximab, as measured by the cumulative area under the curve (AUC). They also noted that AUC (time dependent) is a surrogate marker of time.

Source: Clinical Gastroenterology and Hepatology - November 26, 2020 Category: Gastroenterology Authors: Antoine Petitcollin, Guillaume BOuguen Tags: Letter to the Editor Source Type: research